All In Biotech

Drug Trial Radar · NCT07637162

Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia

An Open-Label Study to Assess the Long-Term Safety and Efficacy of AXS-14 in the Management of Fibromyalgia

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

300

Planned (sponsor's estimate)

Start

Apr 29, 2026

Primary completion

May 2028

Study completion May 2028

Sponsor

Lead sponsor
Axsome Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multi-center, 52-week, open-label trial to evaluate the long-term safety and efficacy of AXS-14 in the management of fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

  • AXS-14 (esreboxetine)Drug

    AXS-14 tablets taken twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Long-term SafetyTime frame: Up to 52 weeks.

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Site

    Little Rock, Arkansas

  • Clinical Research Site

    Anaheim, California

  • Clinical Research Site

    Oceanside, California

  • Clinical Research Site

    Redlands, California

  • Clinical Research Site

    Sacramento, California

  • Clinical Research Site

    Santa Ana, California

  • Clinical Research Site

    Cromwell, Connecticut

  • Clinical Research Site

    Hollywood, Florida

  • Clinical Research Site

    Jacksonville, Florida

  • Clinical Research Site

    Lakeland, Florida

  • Clinical Research Site

    Orlando, Florida

  • Clinical Research Site

    Orlando, Florida

  • Clinical Research Site

    Tampa, Florida

  • Clinical Research Site

    The Villages, Florida

  • Clinical Research Site

    Atlanta, Georgia

  • Clinical Research Site

    Norcross, Georgia

  • Clinical Research Site

    Chicago, Illinois

  • Clinical Research Site

    Overland Park, Kansas

  • Clinical Research Site

    Overland Park, Kansas

  • Clinical Research Site

    Louisville, Kentucky

  • Clinical Research Site

    Prairieville, Louisiana

  • Clinical Research Site

    Boston, Massachusetts

  • Clinical Research Site

    Watertown, Massachusetts

  • Clinical Research Site

    Hazelwood, Missouri

  • Clinical Research Site

    Springfield, Missouri

  • Clinical Research Site

    Town and Country, Missouri

  • Clinical Research Site

    Las Vegas, Nevada

  • Clinical Research Site

    Brooklyn, New York

  • Clinical Research Site

    Williamsville, New York

  • Clinical Research Site

    Tulsa, Oklahoma

  • Clinical Research Site

    Duncansville, Pennsylvania

  • Clinical Research Site

    Charleston, South Carolina

  • Clinical Research Site

    Knoxville, Tennessee

  • Clinical Research Site

    Memphis, Tennessee

  • Clinical Research Site

    Austin, Texas

  • Clinical Research Site

    Austin, Texas

  • Clinical Research Site

    Dallas, Texas

  • Clinical Research Site

    Prosper, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.